the trajectory of Dr Lebby and LWLG next-gen P2IC Platform

New Post Public Reply Private Reply Replies (0) Message Board
proto
659
the trajectory of Dr Lebby and LWLG next-gen P2IC Platform in 2018 has been off the charts incredible!

March 2018 - Lightwave Logic Successfully Demonstrates Packaged Polymer Modulators Designed for 50Gbps

http://lightwavelogic.com/profiles/investor/R...&G=914

March 2018 - Dr. Michael Lebby receiving the PIC Entrepreneur and Business Leader award for 2018

http://lightwavelogic.com/DrLebbyPicAward2018

June 2018 - World Roadmapping Forum for the Photonics Industry

Check out Slide 16 to see what the Roadmap deemed level of Importance for future developments, they took 100 points and allocated that total amongst areas of concern for development, the top two point getters were

1) test equipment for 100Gbs (got 21 pts)
2) Must operate at 100 Gbs NRZ ( got 16 pts)

no other entry got double digit points assigned to it

http://www.h2magazine.nl/iPDF/wtmf17/180622_W...s_iPDF.pdf


September 2018 - ECOC Presentation Download from Lightwave Logic's Website, here is the link >>

http://lightwavelogic.com/Presentations

Industry perception and reality…

• Industry perception
– We (the Industry) are stuck at ~35-50 Gbaud bandwidth. Everything else has to come from increasing complexity of modulation schemes and electronics
• Reality:
– We (LWLG) can use polymer modulators for 100 Gbaud or more!
– E.g. 100Gbps single lane NRZ, 400Gbps with 4 lanes NRZ, 800 Gbps with 4 lanes PAM4

• Industry perception
– Voltages will be high like other MZ modulators
• Reality:
– ~1V means we can eliminate drivers, use direct drive from CMOS

• Industry perception
– Polymer modulators are huge, stand-alone devices
• Reality:
– 5mm Mach-Zehnder fits into standardized transceiver footprints
– Hybrid integration possible with InP, Si photonics, etc. ?

Polymer modulators are the ticket to the next speed node…

So what Platform can deliver 100Gbs NRZ ????

hmmm, all the Legacy Platforms are stuck at 35-50Gbs

ONLY Lightwave Logic (LWLG) can deliver 100Gbs NRZ

And ONLY Lightwave Logic (LWLG) can bring costs down to $1/Gb to meet Industry needs and break through the "purple brick wall"!

October 2018 - Open Letter (excerpt) >>

We have received feedback that our P2IC™ platform with tiny 100Gbaud polymer modulators with low voltage electrical bias are extremely attractive for the next generation fiber optic transceivers. At the recent ECOC conference (European Conference on Optical Communications) we heard potential customers express concerns about technological limits of conventional technologies. This prestigious commercial trade show is where leading companies market their products and plan purchases of optoelectronics equipment. Our talk there spoke directly to addressing those concerns. In the highly visible Market Focus session [1] we showed that our polymer modulators have industry-matching performance at 50Gbaud, but also the capability of breaking these technological limits at 100Gbaud. A Tier 1 customer prospect for our modulators said, "you guys are in the forefront right now".

http://lightwavelogic.com/profiles/investor/R...&G=914

Think about that, who were the Tier 1 presenters at ECOC, Facebook, Intel etc. and they believe LWLG is now in the lead over all other competitors!

November 2018 - White Paper Released on LWLG Website

How Fiber Optics Painted Itself into a Corner and How Electro-Optic Polymers Can Get It Out

http://lightwavelogic.com/Profiles/Investor/I...Validate=3

Excerpt >>

Recall that two different solutions for 400G are shown in Figure 2. One reason that multiple solutions exist is discomfort with the use of 8 lanes. Parallelism beyond 4 lanes has not proved economical or small enough previously. But the industry is even more leery of increasing the modulation complexity. Complex modulation schemes are more sensitive to noise and are more error-prone. Notice that in Figure 3 the difference in PAM4 levels is only 1/3 has much as for NRZ. As a result, the optoelectronics on both transmit and receive ends must distinguish between these smaller differences in signal level. They require power-hungry signal processing electronics not only to encode and decode the data but to offset these errors. The industry already has experience with very complex modulations schemes (e.g. the gray and black circles in Figure 1) and deems them too large, too power-hungry, and way too expensive—in other words, practical only for national backbone networks. Moreover, they are approaching fundamental limits.

LWLG has the solution now! It is a simple solution! While the Industry Legacy devices are stuck at 35-50 Gbaud LWLG has already proven devices that operate at 130Ghz/160Gbs, and with Fempto-second proven response TIME of the LWLG material systems, these standalone speeds can go even MUCH faster, standalone devices in excess of 1 Terabit/sec are achievable for LWLG, no competitor is remotely close to this ability!

So while the Industry Legacy technologies are forced to use complex modulation schemes to advance their speeds to the next node at 400Gbs and beyond, LWLG can provide simple cheap reliable NRZ, OOK devices at 400Gbs, and even 800Gbs in next-next node! LWLG is only just begun!



#CongratsTeamLWLG

Lightwave Logic Inc (LWLG) Stock Research Links

LWLG Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 313

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Updated Category News Views 193

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 128

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 130

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 258

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 224

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 332

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Updated Category News Views 134

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 541

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Tennessee's Bold Lung Cancer Trial Signals Innovation

Updated Category News Views 161

The Heartbeat of Innovation in Cancer Therapy Who would've thought Tennessee would be at the forefront of a global push against lung cancer? Sure, there's Nashville's music scene, but it's the researchers at Tennessee Oncology who are grooving to a different beat—one that might just set the rhythm for advanced cancer therapies worldwide. Yeah, it's a trial, but not just...

Continue Reading

Top 5 Most Recently Viewed Articles

Phreesia Announces Q3 Fiscal Year 2025 Financial Results

Updated Category News Views 71

Phreesia to Release Fiscal Q3 2025 Results Soon Phreesia, Inc. (NYSE: PHR) has great news for its stakeholders! The company revealed plans to announce its financial results for the third quarter of fiscal year 2025 right after market closing on a Monday in December. During this quarter, the firm experienced substantial growth and is eager to share the details with the...

Continue Reading
Innovative Water Bowl Design Enhances Pet Hydration Experience

Updated Category News Views 374

Revolutionary Pet Water Bowl Crafted for Optimal Hydration Every pet owner knows the importance of keeping their furry friends hydrated, especially during hot days. A new invention promises to enhance the experience for pets and their owners alike. This innovative water bowl, known as the THERMA DRINK, is designed with features that cater directly to pet needs. The idea...

Continue Reading
HPH's Leadership Changes Signify Strategic Direction Ahead

Updated Category News Views 177

Leadership Transitions at HPH Highest Performances Holdings Inc. (NASDAQ: HPH) has recently seen a notable change in its Board of Directors. The company announced that Mr. Peh Chin Hua's tenure as Director has come to an end, effective immediately. This decision is part of a broader strategy aimed at strengthening the Board's overall composition and capabilities. Current...

Continue Reading
Apranga Group Reports Growth in Retail Turnover for 2025

Updated Category News Views 132

Apranga Group Retail Performance Overview for 2025 Apranga Group, a major player in the retail sector, has announced its impressive financial performance for the first six months of 2025, demonstrating notable growth compared to the prior year. The company's retail turnover reached a commendable EUR 166.1 million, reflecting a 2.8% increase from the same period in 2024....

Continue Reading
IMUNON Unveils Promising New Vaccine Data for COVID-19

Updated Category News Views 154

New Vaccine Insights from IMUNON's Phase 1 Clinical Trial The innovative PlaCCine technology platform developed by IMUNON, Inc. (NASDAQ: IMNN) promises remarkable durability and advantages over traditional mRNA vaccines, particularly in the struggle against COVID-19. Robust Results from IMNN-101 Vaccine Trials In an encouraging announcement, IMUNON shared pivotal data...

Continue Reading